Ponesimod

Drug Profile

Ponesimod

Alternative Names: ACT-128800; Compound 8bo - Actelion; R-3477; RG 3477

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Actelion Pharmaceuticals
  • Class Antipsoriatics; Chlorobenzenes; Imines; Phenyl ethers; Small molecules; Thiazolidines
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Graft-versus-host disease
  • Phase I Immunological disorders
  • No development reported Plaque psoriasis

Most Recent Events

  • 08 Sep 2016 Phase-III clinical trials in Multiple sclerosis (Adjunctive treatment) in Hungary (PO, Tablet) (EudraCT2012-000541-12)
  • 22 Jun 2015 Phase-II development for Multiple sclerosis completed in Australia, Canada, European Union, Israel, Russia, Switzerland, Ukraine and Serbia
  • 12 May 2015 Phase-III clinical trials in Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top